

NeuroMetrix To Launch Product Targeted at Diabetes Market at the American Diabetes Association 71st Scientific Sessions

WALTHAM, Mass., Jun 20, 2011 (BUSINESS WIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it expects to meet its planned launch date for its latest product, NC-stat[®] |DPNCheck™, which is a fast, accurate, and quantitative test for the evaluation of systemic neuropathies such as diabetic peripheral neuropathy (DPN). The marketing launch will occur during the exhibition at the American Diabetes Association 71st Scientific Sessions in San Diego, CA on June 24-28, 2011.

NC-stat DPNCheck measures sural nerve conduction velocity and amplitude, which are standard biomarkers for DPN. The device is a modified version of the widely used NC-stat[®] device which has been shown to accurately detect DPN². Potential clinical benefits of sural nerve conduction obtained at the point-of-care include:

- | Early detection of DPN, even in the absence of clinical symptoms and signs
- | Help with confirmation or rule-out of DPN and quantification of severity
- | Monitoring changes in DPN over time and in response to treatment

NC-stat DPNCheck will be commercially available in the second half of the year. To learn more, [click here](#).

The Company has a number of activities scheduled during the American Diabetes Association 71st Scientific Sessions. This includes presentation of two posters from accepted abstracts, live demonstrations of NC-stat DPNCheck, and a meeting of its diabetes scientific advisory board (SAB). The SAB has played an important role in guiding the development of NC-stat DPNCheck, and includes:

- | David G. Armstrong, DPM, MD, PhD
- | Andrew J.M. Boulton, MRCP (UK), MD, FRCP
- | Neil H. Brooks, MD, FAAFP
- | Bruce A. Perkins, MD, MPH, FRCP[®]
- | Solomon Tesfaye, MB, ChB, MD, FRCP (UK)
- | Aaron I. Vinik, MD, PhD, FCP, FACP
- | Dan Ziegler, MD, FRCPE

NeuroMetrix encourages meeting attendees to visit booth #947 to learn more about NC-stat DPNCheck, view a live demonstration, inquire about a no-obligation product evaluation for US based endocrinologists, and meet with NeuroMetrix representatives.

About NeuroMetrix

NeuroMetrix is a science-based health care company improving patient care through neurotechnology. The company develops and markets innovative products for the detection, diagnosis, and monitoring of peripheral nerve disorders such as those associated with diabetes and carpal tunnel syndrome. For more information, please visit www.neurometrix.com.

References

¹Perkins BA, Orszag A, Grewal J, NG E, Ngo M, Brill V. Validation of a Novel Point-of-Care Nerve Conduction Device for the Detection of Diabetic Sensorimotor Polyneuropathy. *Diabetes Care*. September 2006;29(9): 2023-2027. ²Perkins BA, Orszag A, Grewal J, NG E, Ngo M, Brill V. Multi-Site Testing with a Point-of-Care Nerve Conduction Device Can Be Used in an Algorithm to Diagnose Diabetic Sensorimotor Polyneuropathy. *Diabetes Care*. March 2008;31(3): 522-524.

SOURCE: NeuroMetrix, Inc.

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
CFO
neurometrix.ir@neurometrix.com

